Farxiga Legal & Patent Challenges: FDA Approvals, Label History, and Safety

FDA Approval Timeline: From Diabetes to Heart and Kidney Disease

Dapagliflozin's path through FDA review was not straightforward. The agency initially rejected AstraZeneca's first New Drug Application (NDA 202293) in January 2012, citing concerns about bladder cancer signals observed in clinical trials and requesting additional data. AstraZeneca resubmitted, and FDA granted approval on January 24, 2014, for adults with type 2 diabetes as an adjunct to diet and exercise to improve glycemic control.

That initial approval came with conditions: AstraZeneca was required to conduct five post-marketing studies, including a dedicated cardiovascular outcomes trial and a bladder cancer follow-up study.

The 2020 Heart Failure Indication

On May 5, 2020, FDA approved Farxiga for a second indication: reducing the risk of cardiovascular death and worsening heart failure in adults with heart failure with reduced ejection fraction (HFrEF). This approval was supported by DAPA-HF (NCT03036124, N=4,744), published in the New England Journal of Medicine in 2019. [1]

In DAPA-HF, dapagliflozin 10 mg daily reduced the primary composite endpoint of worsening heart failure or cardiovascular death by a hazard ratio of 0.74 (95% CI 0.65 to 0.85, P<0.001) compared with placebo. The benefit appeared within 28 days of randomization. This was the first SGLT2 inhibitor approved specifically for HFrEF regardless of diabetes status.

The 2021 Chronic Kidney Disease Indication

FDA expanded Farxiga's label again on April 30, 2021, approving it to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease (CKD) at risk of progression. [2]

This approval was based on DAPA-CKD (NCT03036150, N=4,304), where dapagliflozin reduced the primary composite kidney or cardiovascular endpoint by a hazard ratio of 0.61 (95% CI 0.51 to 0.72, P<0.001). The trial was stopped early at the recommendation of the independent data monitoring committee because of the magnitude of benefit observed. [3]

Patent Portfolio and Hatch-Waxman Litigation

Core Patents Listed in the Orange Book

AstraZeneca holds multiple patents covering dapagliflozin, listed in FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book). The foundational compound patent, US7,919,598, covers the chemical entity itself. Additional listed patents cover crystalline forms, pharmaceutical compositions, and methods of treatment. The pediatric exclusivity period, earned when AstraZeneca completed required pediatric studies, extended certain exclusivities by six months beyond the base patent term.

Generic manufacturers filing Abbreviated New Drug Applications (ANDAs) under the Hatch-Waxman framework must certify against each listed patent. Any Paragraph IV certification, claiming a listed patent is invalid or will not be infringed, triggers the 30-month stay and automatic patent litigation.

ANDA Filers and Litigation Outcomes

Multiple generic manufacturers, including Mylan (now Viatris), Sun Pharmaceutical, and others, filed ANDAs with Paragraph IV certifications against Farxiga's Orange Book patents. AstraZeneca filed suit within 45 days in each case, triggering the 30-month stays.

AstraZeneca reached confidential settlement agreements with several ANDA filers, granting authorized generic launch dates that are estimated to fall in the 2026 to 2028 window depending on the specific agreement terms and pediatric exclusivity calculations. These settlement dates are not publicly disclosed in full, which is typical in Hatch-Waxman settlements filed under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

The Federal Trade Commission reviews such settlements for potential "pay-for-delay" elements. As of the date of this article's last review, no FTC enforcement action has been publicly filed specifically targeting dapagliflozin settlement agreements.

Inter Partes Review Challenges at the USPTO

Beyond district court litigation, generic challengers have filed petitions for inter partes review (IPR) at the USPTO's Patent Trial and Appeal Board (PTAB), arguing that certain Farxiga patents are anticipated or obvious in light of prior art in the SGLT2 inhibitor class. PTAB decisions in this area have been mixed across the SGLT2 class broadly. AstraZeneca prevailed in several IPR proceedings defending core claims related to dapagliflozin's crystalline form patents, though specific outcomes vary by petition.

The table below summarizes the regulatory and intellectual property milestones for Farxiga in a format designed for prescriber and compliance teams reviewing formulary placement decisions.

| Year | Event | Regulatory Body | |------|-------|----------------| | 2012 (Jan) | FDA issues Complete Response Letter; rejects first NDA | FDA | | 2012 (Jun) | EMA approves Forxiga (dapagliflozin) in Europe | EMA | | 2014 (Jan) | FDA approves NDA 202293 for T2D | FDA | | 2016 (Mar) | FDA adds Fournier's gangrene warning class-wide | FDA | | 2018 (Aug) | FDA adds lower-limb amputation risk warning (class-wide for SGLT2s) | FDA | | 2020 (May) | FDA approves HFrEF indication | FDA | | 2021 (Apr) | FDA approves CKD indication | FDA | | 2022 (Feb) | FDA updates label to include HFpEF data from DELIVER trial context | FDA | | ~2026-2028 | Estimated authorized generic or first generic entry (per settlement estimates) | USPTO/FDA |

Farxiga Label: What the Current Prescribing Information Actually Says

The current Farxiga label (revised per the most recent FDA action) carries no black-box warning. The Warnings and Precautions section, however, contains five clinically significant items that every prescriber should know.

Diabetic Ketoacidosis

FDA identified a signal for euglycemic diabetic ketoacidosis (DKA) across the SGLT2 class in May 2015, after reviewing 73 cases submitted to the FDA Adverse Event Reporting System (FAERS) from March 2013 through June 2014. [4] Farxiga's label now instructs prescribers to assess patients who present with signs and symptoms of metabolic acidosis, even when blood glucose is below 250 mg/dL.

The label states that dapagliflozin is not indicated for type 1 diabetes, partly because the DKA risk is substantially higher in that population. Two large randomized trials in T1D, DEPICT-1 and DEPICT-2, showed efficacy for glycemic reduction but DKA rates of 2.6% to 3.4% in the dapagliflozin arms versus 0% to 0.4% in placebo, which was the basis for the agency's refusal to grant a T1D indication. [5]

Fournier's Gangrene

A 2018 FDA safety review identified 12 cases of necrotizing fasciitis of the perineum (Fournier's gangrene) in patients taking SGLT2 inhibitors, including dapagliflozin, reported to FAERS between 2013 and 2018. [6] All 12 required surgical intervention; one patient died. The FDA required a new warning in August 2018, and the Farxiga label now includes language directing prescribers to assess patients who present with pain or tenderness, erythema, or swelling in the genital or perineal area.

Lower-Limb Amputation Risk

The CANVAS trial (canagliflozin, a different SGLT2 inhibitor) showed a roughly doubled risk of lower-limb amputation. FDA subsequently required class-wide label language. Farxiga's label carries a warning noting the observed association, though the DAPA-HF and DAPA-CKD trials and the large real-world analyses in the CVD-REAL program did not replicate a statistically significant amputation signal for dapagliflozin specifically. [7]

Prescribers should counsel patients with peripheral artery disease or prior amputations about this potential risk and monitor foot health regularly.

Urinary Tract Infections and Urosepsis

Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported with SGLT2 inhibitors. The Farxiga label cites post-marketing reports, some requiring hospitalization. The mechanism relates to the drug's glucosuric effect creating a more hospitable urinary environment for bacterial growth.

Renal Impairment and eGFR Thresholds

For the T2D indication, dapagliflozin is not expected to provide glycemic benefit in patients with an eGFR <45 mL/min/1.73 m2, because its mechanism requires functional glomerular filtration for sufficient glucosuria. The label allows continued use for renal and cardiovascular protection down to an eGFR <25 mL/min/1.73 m2 per the CKD indication, a nuance that has clinical implications for dose continuation decisions in deteriorating kidney function.

The American Diabetes Association's 2024 Standards of Care specify that SGLT2 inhibitors with proven cardiovascular or renal benefit should be prioritized in patients with CKD (eGFR 20 to 60 mL/min/1.73 m2) and in those with established atherosclerotic cardiovascular disease or heart failure, regardless of baseline HbA1c. [8]

Post-Market Surveillance: What the Evidence Shows After Approval

FDA Sentinel System Analysis

FDA's Sentinel System, a distributed active surveillance network covering over 100 million patients from insurance claims and electronic health records, has monitored SGLT2 inhibitors including dapagliflozin since their respective approvals. Sentinel analyses have generally confirmed the cardiovascular and renal benefits seen in trials while flagging the DKA and Fournier's gangrene signals that prompted label updates. [9]

CVD-REAL and Real-World Effectiveness

The CVD-REAL program, a multinational cohort study across six countries (N=309,056 new users of SGLT2 inhibitors vs. Other glucose-lowering agents), found SGLT2 inhibitor use associated with a 51% lower rate of hospitalization for heart failure and a 46% lower rate of death. Dapagliflozin accounted for the majority of SGLT2 inhibitor prescriptions in the Nordic countries included in the analysis. [10]

EMA EPAR and European Post-Market Actions

The European Medicines Agency approved Forxiga (the European trade name for dapagliflozin) in June 2012, two years before the FDA. The EMA's European Public Assessment Report (EPAR) has been updated multiple times. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) issued a class-wide review of SGLT2 inhibitors and genital infections in 2016, confirming a causal association and requiring label updates across all EU member states. The EMA also conducted a separate PRAC review of DKA risk, leading to additional contraindications and warnings in the European product information.

The EMA label, unlike the FDA label, explicitly contraindicated dapagliflozin in patients with recurrent genital mycotic infections after the 2016 review, a position the FDA did not mirror directly in the same language, though both labels carry mycotic infection warnings.

Bladder Cancer: Resolution of the Initial Signal

The bladder cancer concern that delayed Farxiga's first FDA approval was addressed through the dedicated post-marketing study required as a condition of the 2014 approval. A pooled analysis of the Farxiga clinical development program and subsequent pharmacoepidemiological studies did not find a statistically significant increased risk of bladder cancer with dapagliflozin use. [11]

The FDA's 2016 label revision removed the explicit bladder cancer warnings that had been present at launch, replacing them with a general note that an imbalance of bladder cancer cases was observed in clinical trials but that available evidence did not establish a causal relationship. This resolution did not affect the drug's market position materially, but it did mark the end of a five-year regulatory uncertainty that had complicated formulary placement decisions.

Competitive and Market Context: SGLT2 Class Dynamics

Farxiga competes in a crowded SGLT2 inhibitor market alongside Jardiance (empagliflozin, Eli Lilly and Boehringer Ingelheim), Invokana (canagliflozin, Janssen), and Steglatro (ertugliflozin, Merck). The cardiovascular outcomes data differs meaningfully across agents, which affects both guideline recommendations and insurer formulary decisions.

How Guideline Bodies Differentiate the Agents

The American College of Cardiology and American Heart Association 2022 Heart Failure Guidelines state: "In patients with HFrEF, SGLT2 inhibitors are recommended to reduce hospitalization for HF and cardiovascular mortality, independent of the presence of type 2 diabetes (Level of Evidence: A)." [12] Both dapagliflozin (based on DAPA-HF) and empagliflozin (based on EMPEROR-Reduced) are named as agents with this Class I recommendation.

The 2023 ACC/AHA Heart Failure Guideline focused clinical update further extended SGLT2 inhibitor recommendations to heart failure with mildly reduced and preserved ejection fraction, citing the DELIVER trial (dapagliflozin, N=6,263) where dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by a hazard ratio of 0.82 (95% CI 0.73 to 0.92, P<0.001). [13]

Patent Cliffs and Generic Entry Implications

When dapagliflozin generics enter the market, pricing dynamics in the SGLT2 class will shift substantially. Canagliflozin, the first SGLT2 inhibitor approved in the United States (March 2013), already has authorized generic competition. The pricing pressure from canagliflozin generics has not yet materially reduced brand Farxiga or brand Jardiance pricing because payers negotiate net prices through rebates, but formulary tier decisions may shift when dapagliflozin generics become available at the estimated 2026 to 2028 window.

For patients paying out of pocket, dapagliflozin's list price as of early 2025 runs approximately $550 to $620 per month for a 30-day supply of 10 mg tablets. AstraZeneca's patient assistance program, AZ&Me, provides free medication to qualifying patients with household incomes at or below 400% of the federal poverty level.

Clinical Prescribing Considerations Given the Regulatory History

Understanding the regulatory history of Farxiga has direct clinical implications. The prescribing checklist below reflects the label's current state after all post-marketing updates.

Before Starting Dapagliflozin

Check eGFR. For the T2D glycemic indication, an eGFR <45 mL/min/1.73 m2 means the drug will not lower glucose meaningfully. For the CKD or HF indication, continue the drug down to eGFR <25 mL/min/1.73 m2 unless the patient is on dialysis.

Screen for risk factors for DKA: low carbohydrate diet, history of DKA, type 1 diabetes (in which case the drug is contraindicated), reduced insulin doses, heavy alcohol use, or planned surgery. The label recommends holding dapagliflozin at least 3 days before scheduled surgery to reduce perioperative DKA risk.

Ask about prior genital mycotic infections. Patients with recurrent vaginal yeast infections or balanitis may experience recurrence on dapagliflozin. This does not mandate avoiding the drug, but counseling at initiation improves adherence.

Monitoring on Therapy

Renal function should be checked before starting, at 4 to 8 weeks after initiation, and then periodically. Electrolytes warrant attention in patients on loop diuretics, because dapagliflozin has modest natriuretic and diuretic effects that may compound volume depletion. Blood pressure should be monitored given the consistent 3 to 5 mmHg systolic blood pressure reduction seen across the key trials.

According to HealthRX's internal review of prescriber queries submitted between January and June 2025, the single most common clinical question about dapagliflozin was whether to continue the drug when eGFR drops below 45 mL/min/1.73 m2 in a CKD patient who started on the drug for glycemic control. The answer, per the current label and the DAPA-CKD data, is yes: continue for renal and cardiovascular protection down to eGFR <25 mL/min/1.73 m2, and hold only when dialysis begins or eGFR falls below that threshold.

Farxiga Safety: The Complete Warning Profile at a Glance

| Warning | Mechanism | Action Required | |---------|-----------|----------------| | Euglycemic DKA | SGLT2-driven insulin-glucagon ratio shift | Hold 3 days pre-surgery; assess any acidosis presentation | | Fournier's gangrene | Glucosuria promoting perineal anaerobic infection | Urgent surgical evaluation if perineal pain/swelling | | Genital mycotic infections | Glucosuria as growth medium | Counsel at initiation; treat standard | | UTI/urosepsis | Glucosuria facilitating ascending infection | Evaluate fever, dysuria, flank pain promptly | | Volume depletion | Osmotic diuresis | Hold in acute illness; caution with loop diuretics | | Hypoglycemia (rare) | Only when combined with insulin or sulfonylurea | Reduce insulin/SU dose at initiation | | Lower-limb amputation (class signal) | Unclear; volume depletion and peripheral vascular effects postulated | Monitor feet; caution in PAD patients | | Bladder cancer (resolved signal) | Not established causally | No current monitoring required per label |